Get the Stockscreener App
7.05
5.24%
-0.39
Passage Bio Inc stock is traded at $7.05, with a volume of 51,320.
It is down -5.24% in the last 24 hours and up +2,029% over the past month.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
See More
Previous Close:
$7.44
Open:
$7.44
24h Volume:
51,320
Relative Volume:
0.15
Market Cap:
$22.00M
Revenue:
-
Net Income/Loss:
$-68.80M
P/E Ratio:
-6.0256
EPS:
-1.17
Net Cash Flow:
$-59.06M
1W Performance:
+33.78%
1M Performance:
+2,029%
6M Performance:
+1,123%
1Y Performance:
+668.81%
1-Day Range:
$6.86
$7.566
1-Week Range:
$5.32
$7.6996
52-Week Range:
$0.257
$7.6996
Passage Bio Inc Stock (PASG) Company Profile
Name
Passage Bio Inc
Sector
Industry
Phone
(267) 866-0312
Address
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
7.05 | 23.21M | 0 | -68.80M | -59.06M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Sep-03-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-08-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-19-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-01-21 | Initiated | Raymond James | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Mar-04-21 | Upgrade | Goldman | Neutral → Buy |
| Feb-04-21 | Initiated | Guggenheim | Buy |
| Jan-25-21 | Initiated | Wedbush | Outperform |
| Jan-04-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Aug-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-25-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-25-20 | Initiated | Chardan Capital Markets | Buy |
| Mar-24-20 | Initiated | Cowen | Outperform |
| Mar-24-20 | Initiated | Goldman | Buy |
| Mar-24-20 | Initiated | JP Morgan | Overweight |
View All
Passage Bio Inc Stock (PASG) Latest News
How strong is Passage Bio Inc. company’s balance sheetRetirement Planning Forecasts For Consistent Profits - jammulinksnews.com
Historical volatility pattern of Passage Bio Inc. visualizedFree Investment Playbook for Growing Markets - Newser
What machine learning models say about Passage Bio Inc.Forecasting Stock Moves with AI Insights - Newser
Real time social sentiment graph for Passage Bio Inc.Daily Market Movers Screener with Filters - Newser
What moving averages say about Passage Bio Inc. Weekly Breakout Forecast with Entry Zones - Newser
What machine learning models say about Passage Bio Inc. Accurate Forecast System with AI Support - Newser
Does Passage Bio Inc. stock perform well during market downturnsExplosive trading opportunities - jammulinksnews.com
What is the dividend policy of Passage Bio Inc. stockBreakout stock performance - jammulinksnews.com
What are Passage Bio Inc. company’s key revenue driversBuild a diversified portfolio for risk management - jammulinksnews.com
What are the latest earnings results for Passage Bio Inc.Superior trading gains - jammulinksnews.com
What are analysts’ price targets for Passage Bio Inc. in the next 12 monthsDiscover breakthrough stocks with expert help - jammulinksnews.com
What analysts say about Passage Bio Inc. stock outlookReliable High Profit Alerts - metal.it
Will Passage Bio Inc. Stock Benefit from AI and Green Energy TrendsFree Stock Market Expert Consultation - Newser
Is Passage Bio Inc. Stock a Good Fit for Conservative InvestorsRisk Controlled Trading Ideas - Newser
Why Passage Bio Inc. stock attracts strong analyst attentionFree Discussion Group - Newser
Passage Bio Skyrockets 31.04%—Is Institutional Buying the Catalyst for a Biotech Breakout? - AInvest
What analysts say about Passage Bio Inc. stockFree Trading Psychology Coaching - Autocar Professional
Passage Bio Soars 12.39% on Institutional Buying Spree - AInvest
What drives Passage Bio Inc. stock priceAccelerated financial growth - PrintWeekIndia
Passage Bio Inc. Stock Analysis and ForecastHigh-performance investment picks - Autocar Professional
Will Passage Bio Inc. stock benefit from interest rate changesAccelerated earnings growth - jammulinksnews.com
What makes Passage Bio Inc. stock price move sharplyStable Growth Stock Picks - Newser
Lynx1 capital buys Passage Bio (PASG) shares worth $733,825 - Investing.com
Is Passage Bio Inc. a good long term investmentFree Stock Movement Tracking - jammulinksnews.com
Passage Bio Inc Stock (PASG) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.32%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):